AGIO vs JCI · rev $65.5M vs P/E 44, rev $23.60B
Agios Pharm (AGIO) versus Johnson Controls International PLC (JCI) — a side-by-side from cached financials, not a winner call.
Agios Pharm (AGIO) is a biotechnology company listed on US.
Johnson Controls International PLC (JCI) is a building products & equipment company listed on NYSE.
Latest reported AGIO revenue for 2026-06-30 was $65.5M. Net income was -$199.8M. AGIO currently screens at market cap $1.68B.
Latest reported JCI revenue for 2025-09-30 was $23.60B. Net income was $3.51B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
AGIO currently screens at market cap $1.68B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
Not investment advice. Open the AGIO and JCI stock pages for the full models.
Not investment advice.